Business Weekly - Cambridge, UK

NHS Trusts are using the company’s flagship product, OptoMize iP, to monitor the condition of hundreds of thousands of diabetes patients in large scale community eye screening programmes that are currently underway across the UK, as government screening targets require 100 per cent of the diabetic population to have had access to a digital scan of their eyes by 2007.

In the US, over 100 private practices, hospitals and universities use DH’s software to screen patients for diseases such as glaucoma, retinopathy, cataracts and macular degeneration, as well as for

longitudinal studies that measure the impact of new healthcare treatments.

Winchester joins DH as President and Board Director, assuming full operational and management responsibility to grow the business in North

America, particularly in the key areas of messaging and high capacity imaging in chronic disease, clinical ophthalmology and clinical trials.

Winchester previously enjoyed a successful 22 year career with Misys

Healthcare Systems, one of the top five healthcare IT companies in North America where he held a variety of senior positions, including Senior

Vice President of Sales and Marketing for the ambulatory business unit, and was most recently in charge of market development for the Healthcare

Division.